Anktiva
(Nogapendekin Alfa)Phase 2Small molecule
This medication is used to treat a specific type of bladder cancer when initial treatment with BCG therapy alone hasn't worked effectively. It works by stimulating the immune system to recognize and attack cancer cells in the bladder.[1] Anktiva is currently being investigated across 2 indications[3], with its most advanced program in Phase 2.[1]
Anktiva is one of 38 small molecule programs targeting Lynch syndrome. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1PORTRAZZA
Eli LillyPreclinical
Lenvima
EisaiPreclinical
Anktiva
SSWOG Cancer Research Network
Phase 2
Ofev
Boehringer IngelheimPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
REGN2810
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nogapendekin Alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSWOG Cancer Research Network